Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Prostamax
Prostamax is the tetrapeptide Lys-Glu-Asp-Pro (KEDP), one of the short synthetic bioregulators developed at the St.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range1 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range5 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Prostamax
What published studies and recent community write-ups report about amounts, timing and course length. 2 preclinical and 4 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical2 rows | |||||
| Preclinical: chronic aseptic prostatitis in rats60 male Wistar rats with surgically induced chronic aseptic prostate inflammation, with 20 control animals | 20 mcg/kg (comparators: Samprost 20 mcg/kg intramuscular, Prostamol Uno 50 mg/kg by gavage) | Once daily | Intramuscular injection | 15 days, starting 30 days after the operationNot applicable | Modern Research in Inflammation (Scientific Research Publishing)2013 |
| Prostate density fell from 1.05 to 0.98 g/cm3 against control and signs of chronic inflammation (swelling, vascular congestion, lymphoid infiltration) decreased, with less sclerosis and atrophy than in the two comparator products. This is a single preclinical study in one laboratory, published in a low-profile journal and not indexed on PubMed, and the authors also report an increase in sexual activity that was not blinded. | |||||
| Preclinical: organ culture of prostate tissue from young and old ratsExplants of heart, lung, prostate and pancreas from 3-week-old and 18-month-old rats | 0.05 ng/mL | Single addition to the culture | In vitro, organotypic tissue culture | Not applicableNot applicable | Advances in Gerontology (PubMed)2006 |
| Each peptide stimulated growth only in the tissue it is assigned to, with Prostamax acting on prostate explants from both young and aged animals at this single concentration. The study tested one concentration and reports tissue specificity rather than any functional prostate outcome, and the chromatin work on human lymphocytes from donors aged 75 to 88 is from the same research network. | |||||
| Community-reported4 rows | |||||
| Community subcutaneous course | 1-2 mg per injection; the reported Russian clinic course is described only as a low microgram-per-kilogram amount | Daily or every other day | Subcutaneous injection; the historical Khavinson framework used oral or sublingual dosing | 10-20 days per courseExtended off-period of several months; courses repeated once or twice a year | Community resource2026 |
| Verified in June 2026, this page states that no regulator has approved a Prostamax dose, that the figures come from forums and vendor packaging with no pharmacokinetic basis, and that subcutaneous bioavailability of KEDP in people has never been characterised. It separates the community injection protocol from the clinic course it describes as documented only in Russian-language sources. | |||||
| Reconstitution reference for a 5 mg vial | 1-2 mg per injection (1 mg is 40 units at 2.5 mg/mL from a 5 mg vial in 2 mL) | Every other day | Subcutaneous injection | About 10 days of supply per 5 mg vial at 1 mg every other dayExtended off-period between courses | Community resource2026 |
| This calculator page works the arithmetic both ways, noting that 1 mL of diluent instead of 2 doubles the concentration and halves the draw to 20 units, and that the reconstituted vial should be used within about 28 days. It repeats that the dose itself is community-sourced from forums and vendor packaging with no indexed pharmacokinetic support. | |||||
| Course protocol from a 20 mg vial | 1-2 mg per administration (1 mg is 0.1 mL, about 10 units, from a 20 mg vial in 2 mL at 10 mg/mL) | Once daily across the course | Subcutaneous or intramuscular injection | 10-20 days per courseCourses sometimes repeated after a break | Community resource2026 |
| This July 2026 guide stresses that the short-course pattern is inherited from how the Prostatilen tissue extract was given rather than from any study of the synthetic peptide, and that the only verified study of KEDP looked at chromatin and cellular aging rather than prostate disease. It states plainly that synthetic Prostamax has not been shown to treat prostatitis or benign prostatic hyperplasia. | |||||
| Microgram vendor figures | 100-200 mcg per day subcutaneously, or 200-500 mcg per day by mouth | Once daily | Subcutaneous or oral | 10-20 daysRest periods between cycles | Community resource2026 |
| This April 2026 review records the much smaller microgram figures some vendors publish and says they are not derived from any dose-finding study, appearing instead to be borrowed from other Khavinson peptides or from the concentration of the Prostatilen extract. It notes that the rat prostatitis study's route is not stated in the English abstracts available to it and that no human dose has been established by any published study. | |||||
How a course is commonly described
- Days 1-10Community-reported
Community protocols run 1-2 mg once daily or every other day by subcutaneous or intramuscular injection, with no titration. Vendor pages that quote micrograms instead describe 100-200 mcg a day over the same window, a difference of roughly tenfold with no way to tell which figure anyone is using.
- Days 10-20Community-reported
The course ends somewhere between 10 and 20 days, which is the standard Khavinson block applied across the whole peptide family rather than anything derived for KEDP. The one animal study that exists dosed for 15 days, which sits inside that window by coincidence rather than by design.
- Between coursesCommunity-reported
Guides describe several months off and one or two courses a year, on the premise that short pulses are enough and continuous use is not the intended pattern. No study has tested a repeat interval or a washout for this peptide.
- Preclinical comparisonPreclinical
The rat study gave 20 mcg/kg intramuscularly for 15 days, which for a 70 kg person would scale to roughly 1.4 mg by body weight, and the culture work used 0.05 ng/mL. Neither was designed to establish a human dose, and no animal study tested more than one amount.
- No human study of Prostamax has been published or registered, so there is no validated dose, route, schedule or safety record. The 1-2 mg injections and 10-20 day courses are vendor and forum conventions, and community sources that publish them say so.
- Prostamax is not Prostatilen. The prostate clinical literature from Russian urology belongs to that injectable tissue extract (also sold as Vitaprost), and nothing from it transfers to the synthetic tetrapeptide.
- No pharmacokinetic measurement exists. A tetrapeptide would be expected to break down quickly in plasma, and the only mechanism evidence is chromatin decondensation in cultured lymphocytes plus docking work suggesting KEDP could be carried into cells by the LAT and PEPT transporters.
Sources for this section (10)
- Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats (Russian)
- Effects of short peptides on lymphocyte chromatin in senile subjects
- Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) (Russian)
- Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters
Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Prostamax is the tetrapeptide Lys-Glu-Asp-Pro (KEDP), one of the short synthetic bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson and assigned in that scheme to the prostate. The published work is small and almost entirely Russian or Georgian: one rat study of chronic aseptic prostatitis in which 20 mcg/kg given intramuscularly for 15 days reduced signs of inflammation and prevented sclerotic and atrophic change, an organ-culture study in which 0.05 ng/mL stimulated prostate explants from young and aged rats, and several chromatin experiments on lymphocytes from donors in their late seventies and eighties that report decondensation of tightly packed chromatin. There is no human trial, no registered study, no pharmacokinetic data and no approval from any Western regulator; Prostamax is sold as a supplement in Russia and as a 5 or 20 mg research vial in the West. Readers should also note that the prostate clinical record often cited alongside it belongs to Prostatilen, an injectable prostate tissue extract, not to this synthetic peptide.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Research on Prostamax
Scientific findings and therapeutic applications
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Research on Prostamax
Scientific findings and therapeutic applications
Amounts recorded for Prostamax
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Dose · lower endpointSign in for schedule, duration and source context.1 mg
- 2Dose · upper endpointSign in for schedule, duration and source context.5 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Lys-Glu-Asp-Pro
Also listed as
Prostamax, KEDP, Lys-Glu-Asp-Pro, SCHEMBL6660498, EX-A10561
InChIKey
WUCUNGRTSFLCLI-XUXIUFHCSA-N
IUPAC name
(2S)-1-[(2S)-3-carboxy-2-[[(2S)-4-carboxy-2-[[(2S)-2,6-diaminohexanoyl]amino]butanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.